Literature DB >> 33466385

Co-Overexpression of TWIST1-CSF1 Is a Common Event in Metastatic Oral Cancer and Drives Biologically Aggressive Phenotype.

Sabrina Daniela da Silva1,2, Fabio Albuquerque Marchi3, Jie Su2, Long Yang4, Ludmila Valverde1, Jessica Hier1, Krikor Bijian2, Michael Hier1, Alex Mlynarek1, Luiz Paulo Kowalski3, Moulay A Alaoui-Jamali2.   

Abstract

Invasive oral squamous cell carcinoma (OSCC) is often ulcerated and heavily infiltrated by pro-inflammatory cells. We conducted a genome-wide profiling of tissues from OSCC patients (early versus advanced stages) with 10 years follow-up. Co-amplification and co-overexpression of TWIST1, a transcriptional activator of epithelial-mesenchymal-transition (EMT), and colony-stimulating factor-1 (CSF1), a major chemotactic agent for tumor-associated macrophages (TAMs), were observed in metastatic OSCC cases. The overexpression of these markers strongly predicted poor patient survival (log-rank test, p = 0.0035 and p = 0.0219). Protein analysis confirmed the enhanced expression of TWIST1 and CSF1 in metastatic tissues. In preclinical models using OSCC cell lines, macrophages, and an in vivo matrigel plug assay, we demonstrated that TWIST1 gene overexpression induces the activation of CSF1 while TWIST1 gene silencing down-regulates CSF1 preventing OSCC invasion. Furthermore, excessive macrophage activation and polarization was observed in co-culture system involving OSCC cells overexpressing TWIST1. In summary, this study provides insight into the cooperation between TWIST1 transcription factor and CSF1 to promote OSCC invasiveness and opens up the potential therapeutic utility of currently developed antibodies and small molecules targeting cancer-associated macrophages.

Entities:  

Keywords:  CSF1; EMT; TWIST1; genomic; metastasis; oral squamous cell carcinoma; tumor invasion; tumor-associated macrophages

Year:  2021        PMID: 33466385      PMCID: PMC7795342          DOI: 10.3390/cancers13010153

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  52 in total

1.  Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.

Authors:  Ezra E W Cohen; Denis Soulières; Christophe Le Tourneau; José Dinis; Lisa Licitra; Myung-Ju Ahn; Ainara Soria; Jean-Pascal Machiels; Nicolas Mach; Ranee Mehra; Barbara Burtness; Pingye Zhang; Jonathan Cheng; Ramona F Swaby; Kevin J Harrington
Journal:  Lancet       Date:  2018-11-30       Impact factor: 79.321

2.  Tumor-associated macrophages and survival in classic Hodgkin's lymphoma.

Authors:  Christian Steidl; Tang Lee; Sohrab P Shah; Pedro Farinha; Guangming Han; Tarun Nayar; Allen Delaney; Steven J Jones; Javeed Iqbal; Dennis D Weisenburger; Martin A Bast; Andreas Rosenwald; Hans-Konrad Muller-Hermelink; Lisa M Rimsza; Elias Campo; Jan Delabie; Rita M Braziel; James R Cook; Ray R Tubbs; Elaine S Jaffe; Georg Lenz; Joseph M Connors; Louis M Staudt; Wing C Chan; Randy D Gascoyne
Journal:  N Engl J Med       Date:  2010-03-11       Impact factor: 91.245

3.  Prognostic significance of colony-stimulating factor receptor expression in ipsilateral breast cancer recurrence.

Authors:  M G Maher; E Sapi; B Turner; A Gumbs; P L Perrotta; D Carter; B M Kacinski; B G Haffty
Journal:  Clin Cancer Res       Date:  1998-08       Impact factor: 12.531

4.  Gene expression analysis of macrophages that facilitate tumor invasion supports a role for Wnt-signaling in mediating their activity in primary mammary tumors.

Authors:  Laureen S Ojalvo; Charles A Whittaker; John S Condeelis; Jeffrey W Pollard
Journal:  J Immunol       Date:  2009-12-16       Impact factor: 5.422

Review 5.  Epithelial-mesenchymal transitions: twist in development and metastasis.

Authors:  Yibin Kang; Joan Massagué
Journal:  Cell       Date:  2004-08-06       Impact factor: 41.582

Review 6.  Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis.

Authors:  Arnoud J Templeton; Mairéad G McNamara; Boštjan Šeruga; Francisco E Vera-Badillo; Priya Aneja; Alberto Ocaña; Raya Leibowitz-Amit; Guru Sonpavde; Jennifer J Knox; Ben Tran; Ian F Tannock; Eitan Amir
Journal:  J Natl Cancer Inst       Date:  2014-05-29       Impact factor: 13.506

7.  Immune escape and survival mechanisms in circulating tumor cells of colorectal cancer.

Authors:  Gunnar Steinert; Sebastian Schölch; Thomas Niemietz; Naoki Iwata; Sebastián A García; Bianca Behrens; Anita Voigt; Matthias Kloor; Axel Benner; Ulrich Bork; Nuh N Rahbari; Markus W Büchler; Nikolas H Stoecklein; Jürgen Weitz; Moritz Koch
Journal:  Cancer Res       Date:  2014-03-05       Impact factor: 12.701

8.  Tissue microarrays for high-throughput molecular profiling of tumor specimens.

Authors:  J Kononen; L Bubendorf; A Kallioniemi; M Bärlund; P Schraml; S Leighton; J Torhorst; M J Mihatsch; G Sauter; O P Kallioniemi
Journal:  Nat Med       Date:  1998-07       Impact factor: 53.440

9.  Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells.

Authors:  Mei Yang; Jingqi Chen; Fang Su; Bin Yu; Fengxi Su; Ling Lin; Yujie Liu; Jian-Dong Huang; Erwei Song
Journal:  Mol Cancer       Date:  2011-09-22       Impact factor: 27.401

10.  Recurrent oral cancer: current and emerging therapeutic approaches.

Authors:  Sabrina Daniela da Silva; Michael Hier; Alex Mlynarek; Luiz Paulo Kowalski; Moulay A Alaoui-Jamali
Journal:  Front Pharmacol       Date:  2012-07-30       Impact factor: 5.810

View more
  3 in total

1.  Portrait of DNA methylated genes predictive of poor prognosis in head and neck cancer and the implication for targeted therapy.

Authors:  Jessica Hier; Olivia Vachon; Allison Bernstein; Iman Ibrahim; Alex Mlynarek; Michael Hier; Moulay A Alaoui-Jamali; Mariana Maschietto; Sabrina Daniela da Silva
Journal:  Sci Rep       Date:  2021-05-11       Impact factor: 4.379

2.  MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer.

Authors:  Manu Prasad; Jonathan Zorea; Sankar Jagadeeshan; Avital B Shnerb; Sooraj Mathukkada; Jebrane Bouaoud; Lucas Michon; Ofra Novoplansky; Mai Badarni; Limor Cohen; Ksenia M Yegodayev; Sapir Tzadok; Barak Rotblat; Libor Brezina; Andreas Mock; Andy Karabajakian; Jérôme Fayette; Idan Cohen; Tomer Cooks; Irit Allon; Orr Dimitstein; Benzion Joshua; Dexin Kong; Elena Voronov; Maurizio Scaltriti; Yaron Carmi; Cristina Conde-Lopez; Jochen Hess; Ina Kurth; Luc G T Morris; Pierre Saintigny; Moshe Elkabets
Journal:  J Immunother Cancer       Date:  2022-03       Impact factor: 12.469

Review 3.  Roles for growth factors and mutations in metastatic dissemination.

Authors:  Nishanth Belugali Nataraj; Ilaria Marrocco; Yosef Yarden
Journal:  Biochem Soc Trans       Date:  2021-06-30       Impact factor: 5.407

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.